MedPath

Aspartic acid

Generic Name
Aspartic acid
Brand Names
Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %
Drug Type
Small Molecule
Chemical Formula
C4H7NO4
CAS Number
56-84-8
Unique Ingredient Identifier
30KYC7MIAI

Overview

One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/05/08
N/A
Completed
2025/01/24
Phase 2
Active, not recruiting
2024/10/28
Phase 1
Withdrawn
2024/10/15
Phase 1
Completed
Uniquity One (UNI)
2024/06/13
Phase 1
Not yet recruiting
2024/04/11
Phase 3
Recruiting
First Affiliated Hospital of Zhejiang University
2024/03/27
Phase 1
Recruiting
2024/03/25
Not Applicable
Recruiting
2024/01/12
Phase 4
Completed
2023/12/13
Phase 1
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
ICU Medical Inc.
0990-7171
INTRAVENOUS
1050 mg in 100 mL
5/4/2022
B. Braun Medical Inc.
0264-4500
INTRAVENOUS
434 mg in 100 mL
4/21/2023
Baxter Healthcare Corporation
0338-1131
INTRAVENOUS
0.19 g in 100 mL
8/4/2022
B. Braun Medical Inc.
0264-1933
INTRAVENOUS
0.32 g in 100 mL
8/22/2022
Fresenius Kabi USA, LLC
63323-712
INTRAVENOUS
99 mg in 100 mL
8/2/2023
ICU Medical Inc.
0990-7172
INTRAVENOUS
700 mg in 100 mL
5/4/2022
Fresenius Kabi USA, LLC
63323-714
INTRAVENOUS
71 mg in 100 mL
8/7/2023
ICU Medical Inc.
0990-4178
INTRAVENOUS
370 mg in 100 mL
9/21/2021
Baxter Healthcare Corporation
0338-1130
INTRAVENOUS
0.32 g in 100 mL
8/4/2022
Baxter Healthcare Corporation
0338-0499
INTRAVENOUS
600 mg in 100 mL
10/7/2020

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
OLIMEL 5.7% E
baxter corporation
02352532
Emulsion - Intravenous
1.65 G / L
1/19/2011
AMINOSYN-PF 10%
hospira healthcare ulc
00731366
Solution - Intravenous
527 MG / 100 ML
12/31/1990
AMINOSYN II 8.5% WITH 50% DEXTROSE
hospira healthcare ulc
00742767
Solution - Intravenous
298 MG / 100 ML
12/31/1988
PRIMENE 10%-LIQ IV
clintec nutrition company
02161192
Liquid - Intravenous
600 MG / 100 ML
12/31/1995
OLIMEL 7.6% E
baxter corporation
02477955
Emulsion - Intravenous
2.2 G / L
10/25/2018
PRIMENE 10%
baxter corporation
02236875
Liquid - Intravenous
600 MG / 100 ML
11/14/1997
AMINOSYN II WITH ELECTROLYTES IN DEXTROSE INJECTION WITH CALCIUM
hospira healthcare ulc
00851574
Solution - Intravenous
298 MG / 100 ML
12/30/1996
AMINOSYN II 7% WITH 10% DEXTROSE
hospira healthcare ulc
00742740
Solution - Intravenous
245 MG / 100 ML
12/31/1988
AMINOSYN II IN DEXTROSE INJECTION
hospira healthcare ulc
00839302
Solution - Intravenous
298 MG / 100 ML
12/31/1991
20% PROSOL
baxter corporation
02141450
Liquid - Intravenous
0.6 G / 100 ML
10/9/1996

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.